A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 04 2020
28 04 2020
Historique:
received:
23
09
2019
accepted:
10
03
2020
entrez:
29
4
2020
pubmed:
29
4
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Defective blood products that are recalled because of safety or potency deviations can trigger adverse health events and constrict the nation's blood supply chain. However, the underlying characteristics and impact of blood product recalls are not fully understood. In this study, we identified 4700 recall events, 7 reasons for recall, and 144 346 units affected by recalls. Using geospatial mapping of the newly defined county-level recall event density, we discovered hot spots with high prevalence and likelihood of blood product recall events. Distribution patterns and distribution distances of recalled blood products vary significantly between product types. Blood plasma is the most recalled product (87 980 units), and leukocyte-reduced products (34 230 units) are recalled in larger numbers than non-leukocyte-reduced products (8076 units). Donor-related reasons (92 382 units) and sterility deviations (22 408 units) are the major cause of blood product recalls. Monetary loss resulting from blood product recalls is estimated to be $17.9 million, and economic sensitivity tests show that donor-related reasons and sterility deviations contribute most to the overall monetary burden. A total of 2.8 million days was required to resolve recall events, and probabilistic survival time analysis shows that sterility deviations and contamination took longer to resolve because of their systemic effect on blood collection and processing. Our studies demonstrate that better donor screening procedures, rigorous sterility requirements, improved containment methods, and mitigation of recall events in high-prevalence regions will enable a more robust blood supply chain.
Identifiants
pubmed: 32343797
pii: S2473-9529(20)31369-0
doi: 10.1182/bloodadvances.2019001024
pmc: PMC7189286
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1780-1791Informations de copyright
© 2020 by The American Society of Hematology.
Références
Transfusion. 2007 Apr;47(4):573-81
pubmed: 17381614
Transfus Med Rev. 1994 Apr;8(2):132-45
pubmed: 8003856
Transfusion. 2015 Jun;55(6):1313-9; quiz 1312
pubmed: 25522888
JAMA. 2018 Feb 27;319(8):825-827
pubmed: 29486023
Transfus Med Rev. 2013 Apr;27(2):82-90
pubmed: 23375736
Biomed J. 2014 Jul-Aug;37(4):211-7
pubmed: 25116717
JAMA. 2016 Nov 15;316(19):2025-2035
pubmed: 27732721
Am Fam Physician. 2011 Mar 15;83(6):719-24
pubmed: 21404983
Transfusion. 2019 Feb;59(2):516-523
pubmed: 30609064
Transfus Med Rev. 2009 Jul;23(3):177-88
pubmed: 19539873
Health Care Manag Sci. 2017 Dec;20(4):548-564
pubmed: 27262292
J Clin Microbiol. 2009 Apr;47(4):1021-4
pubmed: 19171686
Lancet. 2013 May 25;381(9880):1866-75
pubmed: 23706803
Transfus Apher Sci. 2013 Apr;48(2):129-31
pubmed: 23535511
Lancet. 2013 May 25;381(9880):1845-54
pubmed: 23706801
Curr Opin Hematol. 2018 Nov;25(6):500-508
pubmed: 30281037
Blood. 2014 Nov 13;124(20):3052-8
pubmed: 25293771
Transfus Med Rev. 2017 Jan;31(1):62-71
pubmed: 27317382
Transfusion. 2014 Sep;54(9):2276-82
pubmed: 24863173
Blood. 2008 Oct 1;112(7):2617-26
pubmed: 18809775
Transfusion. 2016 Sep;56(9):2173-83
pubmed: 27301995
Transfusion. 2017 Jun;57 Suppl 2:1588-1598
pubmed: 28591469
Transfus Med Rev. 2014 Oct;28(4):226-34
pubmed: 25311469
J Trauma. 2006 Jun;60(6 Suppl):S83-90
pubmed: 16763486
Transfusion. 2017 Jun;57 Suppl 2:1599-1624
pubmed: 28591471
Blood Adv. 2017 May 26;1(14):867-874
pubmed: 29296730
Blood Transfus. 2017 Mar;15(2):145-152
pubmed: 28263172
Br J Anaesth. 2014 Dec;113(6):922-34
pubmed: 24972790
Appl Health Econ Health Policy. 2011;9(1):29-37
pubmed: 21174480
Transfus Med Rev. 2004 Jan;18(1):36-45
pubmed: 14689376